Compositions and methods for cryopreservation of spermatozoa
Patent Information
- Application Number
- PCT/US2024/020104
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-16
- Filing Date
- 2024-03-15
- Publication Date
- 2024-12-26
AI Technical Summary
Cryopreservation of mouse sperm is challenging due to inconsistency in sperm survival and in vitro fertilization (IVF) success rates, primarily attributed to oxidative damage during thawing, which existing methods like CARD-CPA fail to reliably address.
A modified cryoprotective agent (CPA) comprising L-glutamine and monothioglycerol (LM-CPA) is developed, which reduces oxidative damage and enhances IVF success rates by forming a sperm suspension that is cryopreserved in liquid nitrogen and thawed at 37°C for successful embryo generation.
LM-CPA significantly increases IVF success rates and ensures reliable embryo generation from frozen sperm, offering a more consistent and effective method for mouse sperm cryopreservation, applicable to other mammalian species as well.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001]Attorney Docket No.205961-7100WO1(00382) TITLE OF THE INVENTION Compositions and Methods for Cryopreservation of Spermatozoa CROSS-REFERENCE TO RELATED APPLICATION(S) This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No.63 / 452,641, filed March 16, 2023, the contents of which are incorporated by reference herein in their entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under R01AI141787 awarded by the National Institutes of Health. The government has certain rights in the invention BACKGROUND Recent advances in the CRISPR / CAS-mediated modification of the mouse and other mammalian genomes have made it much easier to generate new lines of knock-out or knock-in mice. Consequently, more and more genetically modified mice have been created to facilitate biomedical research. Housing mice is expensive, and it is ethically preferable to keep only the minimum number of mice required for active research. These facts raise the issue of preserving valuable resources, such as genetically modified mice, for future research. The cryopreservation of genetically modified mice can be accomplished by the cryopreservation of sperm, embryos, or eggs. Among these, sperm cryopreservation is the simplest method and can facilitate distribution, due to the small number of mice required and speedy procedures for obtaining live sperm. However, cryopreservation of mouse sperm has been more challenging than that of other species. There is a need in the art to develop robust methods for cryopreservation of mouse sperm that may also be applicable to cryopreservation of sperm from other mammalian species. The present disclosure addresses this unmet need. -1- 51873477.2 Attorney Docket No.205961-7100WO1(00382) SUMMARY In one aspect, provided herein is a composition for cryopreservation of a spermatozoon (sperm) of a subject, wherein the composition comprises a cryoprotective agent (CPA) comprising L-glutamine and monothioglycerol (LM-CPA). In another aspect, provided herein is a composition for cryopreservation of a sperm of a subject, wherein the composition comprises, the sperm, a modified cryoprotective agent (CPA) containing both L-glutamine and monothioglycerol (LM-CPA). In yet another aspect, provided herein is method of cryopreserving sperm of a subject, wherein the method comprises contacting the sperm with the composition as described elsewhere herein to form a sperm suspension and preserving the sperm suspension in a liquid nitrogen. In yet another aspect, provided herein is a method of in vitro fertilization, wherein the method comprises cryopreserving a sperm of a subject, wherein the cryopreserving comprises contacting the sperm with the composition described elsewhere herein to form a sperm suspension, cryopreserving the sperm suspension in a liquid nitrogen, thawing the sperm suspension at about 37°C and contacting the sperm with an egg from a subject to form an embryo. In yet another aspect, provided herein is a kit comprising the composition as described elsewhere herein and an instructional material for use thereof. In certain embodiments, the concentration of monothioglycerol in the composition is about 100-800 µM µM and the concentration of L-glutamine in the composition is about 20-120 mM mM. In certain embodiment, the composition further comprises about 18% D+raffinose pentahydrate and about 3% dehydrated skim milk. In certain embodiments, the composition protects the sperm from damage or death during thawing of the cryopreserved composition. In certain embodiments, the composition exhibits enhanced in vitro fertilization (IVF) rate relative to the CPA devoid of monothioglycerol. In certain embodiments, the subject is a mammal. In certain embodiments, the mammal is selected from the group consisting of a human and a mouse. -2- 51873477.2 Attorney Docket No.205961-7100WO1(00382) BRIEF DESCRIPTION OF THE DRAWINGS For the purpose of illustrating the invention, depicted in the drawings are certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings. FIG.1 shows that cryoprotective agent comprising L-glutamine and monothioglycerol (LM-CPA) is a more reliable medium for Sperm Cryopreservation than CARD-CPA (shown in Table 1). Sperms frozen in either CARD-CPA or LM-CPA were thawed and used for in vitro fertilization in the CARD IVF protocol (T. Takeo et al, Cold Spring Harbor protocols, 2018(6), pdb-prot094524). Sperms and eggs from various mouse lines in C57BL / 6 background were used. At day 2, embryos reached to 2-cell stage were counted out of total eggs used to calculate fertilization rate. Medians were labelled as solid line and quartiles were labelled as dotted line. Average: 57.01% (CARD-CPA); 72.8% (LM-CPA). Sample size: n=34 (CARD-CPA); n=50 (LM-CPA); **: P<0.0023 with student’s t-test. DETAILED DESCRIPTION OF THE INVENTION The generally known CARD method of sperm cryopreservation has occasionally exhibited inconsistency in spermatozoa (sperm) survival or IVF success rate, which has been posited to be due to the differences in cooling rate at the time of cryopreservation. Using mouse embryos and sperm in a C57BL / 6 background for cryopreservation in the laboratory, it was observed that, indeed, the CARD-cryoprotective agent (CARD-CPA) exhibited occasional inconsistency in survival and a wide range of IVF success rates. However, the effort to strictly regulate cooling rates during sperm freezing failed to eliminate this inconsistency in the IVF success rate. Therefore, it was hypothesized that the inconsistency in CARD-CPA is likely due to the oxidative damage that sperm experience during thawing in the straws prior to being transferred to sperm preincubation media containing methyl-β-cyclodextrin (MBCD) and IVF media containing reduced glutathione. The cryoprotective agent (CPA) for mouse sperm was improved by adding either monothioglycerol or L-glutamine. Since the CARD protocol significantly enhanced in vitro fertilization (IVF) rate, compatible CARD-CPA utilizing L-glutamine has been widely used to meet the growing demand for sperm cryopreservation. However, the viability of sperm frozen in -3- 51873477.2 Attorney Docket No.205961-7100WO1(00382) the CARD-CPA is still highly variable, so the success of IVF using thawed sperm cannot be guaranteed. To develop a more reliable technique for mouse sperm cryopreservation that is compatible with the CARD IVF protocol, CARD-CPA and a modified CPA (containing both L- glutamine and monothioglycerol (LM-CPA)), which was designed to reduce oxidative damage to sperm in straws during freezing and thawing, were compared. It was found that LM-CPA reduced the incidence of infertility and significantly increased the IVF success rate. Thus, it was concluded that cryopreservation of mouse sperm in LM-CPA is a method that reliably ensures embryo generation from frozen sperm that may also be applicable to cryopreservation of sperm from other mammals. Definitions As used herein, each of the following terms has the meaning associated with it in this section. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, separation science and organic chemistry are those well- known and commonly employed in the art. It should be understood that the order of steps or order for performing certain actions is immaterial, so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously or not. As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. As used herein, the term “about” is understood by persons of ordinary skill in the art and varies to some extent on the context in which it is used. As used herein when referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. The term “subject” is intended to include living organisms in which an immune response can be elicited (e.g., mammals). A “subject” or “patient,” as used therein, may be a human or -4- 51873477.2 Attorney Docket No.205961-7100WO1(00382) non-human mammal. Non-human mammals include, for example, non-human primates, livestock, and pets, such as simian, ovine, bovine, porcine, canine, feline, and murine mammals. Preferably, the subject is human. Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual and partial numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range. As used herein, an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the compositions and methods of the invention. The instructional material of the kit of the invention may, for example, be affixed to a container which contains the nucleic acid, peptide, and / or composition of the invention or be shipped together with a container which contains the nucleic acid, peptide, and / or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient. Compositions In one aspect, provided herein is a composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises a cryoprotective agent (CPA) comprising L- glutamine and monothioglycerol (LM-CPA). In another aspect, provided herein is a composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises, the spermatozoon, a modified cryoprotective agent (CPA) containing both L-glutamine and monothioglycerol (LM-CPA). In certain embodiments, the concentration of monothioglycerol in the composition is about 100-800 µM. In certain embodiments, the concentration of monothioglycerol is about 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, -5- 51873477.2 Attorney Docket No.205961-7100WO1(00382) 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, and 800 µM. In certain embodiments, the concentration of monothioglycerol in the composition is about 420-460 µM. In certain embodiments, the concentration of monothioglycerol in the composition is about 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460 µM. In certain embodiments, the concentration of monothioglycerol in the composition is about 447 µM. In certain embodiments, the concentration of L-glutamine in the composition is about 20- 120 mM. In certain embodiments, the concentration of L-glutamine in the composition is about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120 mM. In certain embodiments, the concentration of L-glutamine in the composition is about 100 mM. In certain embodiments, the composition further comprises about 15% -25% D+raffinose pentahydrate and about 1%-5% dehydrated skim milk. In certain embodiments, the composition comprises about 18% D+raffinose pentahydrate and about 3% dehydrated skim milk. In certain embodiments, the composition protects the spermatozoon from damage or death during thawing of the cryopreserved composition. In certain embodiments, the composition exhibits enhanced in vitro fertilization (IVF) rate relative to the composition that is devoid of monothioglycerol. Thus, the presently claimed composition comprising MTG and l- glutamine produced a synergistic impact on sperm thawing and IVF rate. The presently claimed composition reduced the incidence of infertility and increased the IVF success rate. In certain embodiments, the subject is a mammal. In certain embodiments, the mammal is selected from the group consisting of a human, a non-human primate, a livestock, a pet such as, for example, a simian, a ovine, a bovine, a porcine, a canine, a feline, and a murine mammal. In certain embodiments, the mammal is a human. In certain embodiments, the mammal is a mouse. Methods In another aspect, provided herein is method of cryopreserving spermatozoon of a subject, wherein the method comprises contacting the spermatozoon with the composition described elsewhere herein to form a suspension and further preserving the suspension in a liquid nitrogen. -6- 51873477.2 Attorney Docket No.205961-7100WO1(00382) In another aspect, provided herein is a method of in vitro fertilization, wherein the method comprises cryopreserving a spermatozoon of a subject, wherein the cryopreserving comprises contacting the spermatozoon with the composition as described elsewhere herein to form a suspension and cryopreserving the suspension in a liquid nitrogen; thawing the spermatozoon suspension at about 37°C; and contacting the spermatozoon with an egg from a subject to form an embryo. In certain embodiments, the spermatozoon is activated in preincubation media containing methyl-beta-cyclodextrin (MBCD). Subsequently, the spermatozoon is added to an IVF media containing an egg. In certain embodiments, the IVF media contains glutathione to reduce the oxidative damage to the spermatozoon and the egg, and to enhance the IVF efficiency. In certain embodiments, the composition protects the spermatozoon from damage or death during the thawing step. In certain embodiments, the method exhibits enhanced in vitro fertilization (IVF) rate relative to the method that uses a CPA devoid of monothioglycerol. In certain embodiment, the subject is a mammal. In certain embodiments, the mammal is selected from the group consisting of a human and a mouse. Kit In certain embodiments, provided herein is kit comprising the composition as described elsewhere herein and an instructional material for use thereof. The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the -7- 51873477.2 Attorney Docket No.205961-7100WO1(00382) invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this invention and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size / volume, and experimental reagents with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application. EXAMPLES The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples, therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure. Materials and methods. Media The composition CARD-CPA is shown in Table 1 as previously described (Takeo, T et al. (2018). Cold Spring Harbor protocols, 2018(6), pdb-prot094516). To make CARD-CPA, 146 mg of L-Glutamine was placed in 10 mL of cell culture-grade water and vortexed for 3 minutes, followed by 3 minutes of incubation in 60 °C water bath. Subsequently, 1800 mg of D+raffinose pentahydrate and 300 mg of dehydrated skim milk were added, and the solution was vortexed for 3 minutes. The solution was incubated further in 60 °C water bath for 90 minutes with 3 minutes of vortexing every 30 minutes. Next, the solution was centrifuged at 10,000g for 60 minutes. The -8- 51873477.2 Attorney Docket No.205961-7100WO1(00382) clear top portion of the supernatant was collected and filtered through a 0.22-μm filter. Final CARD-CPA solution was stored up to 3 months at room temperature. The quality of home-made CARD-CPA was confirmed by comparing it to commercially available CARD FERTIUP CPA (Cosmo Bio USA) during IVF. The modified media with additional monothioglycerol (MTG) was named as LM-CPA (L-Glutamine + MTG cryoprotective agent). To make LM-CPA (Table 1), monothioglycerol (MTG; FW = 108.16; r = 1.295 g / mL) was diluted by placing 10 μL MTG to 2.5 mL of cell culture–grade water, making a 44.7 mM solution of MTG. Then, 100 μL of 44.7 mM solution MTG was added to 10 mL of CARD-CPA and filtered through a 0.22-μm filter. Final solution of LM-CPA was stored at room temperature for up to 3 months. Cryopreservation of sperm For sperm cryopreservation, the following procedures were used for one sperm donor mouse in C57BL / 6 background using either CARD-CPA or LM-CPA. First, 60 μL of cryoprotective reagents was placed into a 35-mm dish, covered with mineral oil, and another 60 μL of cryoprotective reagents was added to the same drop to increase the volume without spreading. The dish was incubated in a 37 °C incubator (6% CO2, 5% O2balanced with N2) at least 30 minutes before spermatozoa collection. A Styrofoam box (15’’w x 14’’d x 10’’h) was filled with 6-9 cm height of LN2, and a small piece of Styrofoam (9’’w x 7’’d) was placed inside floating. A box lid was placed on top, allowing the box to be filled with vapor LN2at least 30 minutes before spermatozoa collection. Six 0.25cc straws (Reproduction Provisions LLC) were prepared for each donor mouse. One sperm donor was euthanized by cervical dislocation; cauda epididymites and vas deferens were removed and immediately placed in the CPA dish taken out from the incubator. Sperm was released by making 6-7 cuts through the epididymis and vas deferens. The plate was rotated for 1 minute to disperse sperm out. The straw was connected to a syringe, and the contents were aspirated in the following order: 100 μL of HTF (Human Tubal Fluid), 15 mm of air, 10 μL of sperm suspension, 15 mm of air. The straw was sealed at both ends with heat sealer. Straws were put in the 145mm flat cassettes (6 straws from one donor mouse in one cassette), and the cassettes were placed on top of Styrofoam float. The lid was closed, and the cassette was incubated in the vapor phase for 10 minutes. After that step, the cassettes were dropped into the liquid nitrogen and transferred to LN2tank for long term storage. -9- 51873477.2 Attorney Docket No.205961-7100WO1(00382) Sperm capacitation medium and fertilization medium TYH (Toyoda, Yokoyama, Hoshi) medium with 0.75 mM MBCD for sperm capacitation (TYH-MBCD) and fertilization medium (Human Tubal Fluid (HTF) medium with 5.14 mM calcium) were prepared according to the CARD method described previously (T. Takeo et al, Cold Spring Harbor protocols, 2018(6), pdb-prot094524; Takeo, T et al. (2018). Cold Spring Harbor protocols, 2018(6), pdb-prot094516). For TYH-MBCD, the composition is provided in Table 2. All reagents were added according to the order in the list except PVA and CaCl2to cell culture-grade water. PVA and CaCl2 were dissolved separately in water and added last. The final volume of the solution was brought to 100 mL and filtered through a 0.22-μm filter. Aliquots were stored at 4°C. For HTF with 5.14 mM calcium, a list of reagents is provided in Table 2. All reagents were added and mixed carefully following the order in the list to cell culture-grade water, except CaCl2. CaCl2 was dissolved in water and added last. Next, the solution was gassed for 5 minutes with mixed gas (6% CO2, 5% O2balanced with N2). BSA was added and allowed to dissolve without stirring. The final volume of the solution was brought to 100 mL and filtered through a 0.22-μm filter. Aliquots were stored at 4°C for up to 3 months. Sperm thawing and capacitation For sperm thawing and capacitation, the following steps were used: first, 90 μL of TYH- MBCD was placed at the center of a 35-mm, covered with mineral oil. The dish was incubated in a 37°C incubator for at least 30 minutes. A straw was removed from LN2and immediately immersed into water in 37°C water bath. After 5 seconds, the straw was removed from the water bath, and wiped with a tissue. Both sealed ends of the straw were cut off, and straws were connected to 1 ml syringe to push out the thawed sperm to 90 μL of TYH-MBCD on the 35-mm dish. In vitro fertilization with thawed sperm was performed using HTF with 5.14 mM calcium and 1 mM reduced glutathione as described elsewhere herein. -10- 51873477.2 Attorney Docket No.205961-7100WO1(00382) -11- 51873477.2 Attorney Docket No.205961-7100WO1(00382) Example 1: In vitro fertilization (IVF) At 24 hours after adding sperm to eggs for IVF, the number of embryos that reached to 2- cell stage were counted and their percentage of the total eggs used was calculated. It was demonstrated that sperm frozen in LM-CPA had a significantly higher IVF success rate than -12- 51873477.2 Attorney Docket No.205961-7100WO1(00382) those frozen in CARD-CPA (median 72% vs.57%) (FIG.1). Importantly, LM-CPA abolished death of thawed sperm and extremely low fertilization rates, which must be eliminated for cryopreservation to be reliable (FIG.1). When occasionally observed under the microscope, it was seen that some sperms thawed from CARD-CPA are extremely mobile in TYH-MBCD, whereas sperms thawed from LM-CPA were less mobile. However, these highly mobile sperms observed occasionally are only a very small portion of the thawed sperms from the same straw and does not have a significant impact on the overall fertilization rate under our IVF conditions with reduced glutathione (FIG.1). Rather, it is believed that it is more important to minimize the risk of sperm damage during thawing in order to improve IVF efficiency, specifically to eliminate the possibility of sperm death and very low fertilization rate (Fig.1). Therefore, it is concluded that LM-CPA containing 18% raffinose, 3% skim milk, L-glutamine, and MTG is more reliable sperm cryopreservation medium than CARD-CPA for ensuring the success of IVF performed using the CARD IVF protocol following sperm thawing. Enumerated embodiments: The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels. Embodiment 1 provides a composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises a cryoprotective agent (CPA) comprising L- glutamine and monothioglycerol (LM-CPA). Embodiment 2 provides a composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises, the spermatozoon, a modified cryoprotective agent (CPA) containing both L-glutamine and monothioglycerol (LM-CPA). Embodiment 3 provides the composition of any one of embodiments 1-2, wherein the concentration of monothioglycerol is about 100-800 µM and the concentration of L-glutamine is about 20-120 mM. Embodiment 4 provides the composition of any one of embodiments 1-3, wherein the composition further comprises about 18% D+ raffinose pentahydrate and about 3% dehydrated skim milk. -13- 51873477.2 Attorney Docket No.205961-7100WO1(00382) Embodiment 5 provides the composition of any one of embodiments 1-4, wherein the composition protects the spermatozoon from damage or death during thawing of the cryopreserved composition. Embodiment 6 provides the composition of any one of embodiments 1-5, wherein the composition exhibits enhanced in vitro fertilization (IVF) rate relative to the CPA devoid of monothioglycerol. Embodiment 7 provides the composition of any one of embodiments 1-6, wherein the subject is a mammal. Embodiment 8 provides the composition of any one of embodiments 1-7, wherein the mammal is selected from the group consisting of a human and a mouse. Embodiment 9 provides a method of cryopreserving spermatozoon of a subject, wherein the method comprises contacting the spermatozoon with the composition of embodiments 1-8 to form a suspension and preserving the suspension in a liquid nitrogen. Embodiment 10 provides a method of in vitro fertilization, wherein the method comprises a. cryopreserving a spermatozoon of a subject, wherein the cryopreserving comprises contacting the spermatozoon with the composition of embodiments 1-8 to form a suspension, and cryopreserving the suspension in a liquid nitrogen; b. thawing the spermatozoon suspension at about 37°C;and c. contacting the spermatozoon with an egg from a subject to form an embryo. Embodiment 11 provides the method of embodiment 10, wherein the composition protects the spermatozoon from damage or death during the thawing step. Embodiment 12 provides the method of embodiments 10-11, wherein the method exhibits enhanced in vitro fertilization (IVF) rate relative to the method that uses a CPA devoid of monothioglycerol. Embodiment 13 provides a kit comprising the composition of any one of embodiments 1- 8 and an instructional material for use thereof. Embodiment 14 provides the method of embodiments 9-12, wherein the subject is a mammal. Embodiment 15 provides the method of embodiments 9-12 and 14, wherein the mammal is selected from the group consisting of a human and a mouse. -14- 51873477.2 Attorney Docket No.205961-7100WO1(00382) Other Embodiments The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations. . -15- 51873477.2
Claims
Attorney Docket No.205961-7100WO1(00382) CLAIMS What is claimed is:
1. A composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises a cryoprotective agent (CPA) comprising L-glutamine and monothioglycerol (LM-CPA).
2. A composition for cryopreservation of a spermatozoon of a subject, wherein the composition comprises, the spermatozoon, a modified cryoprotective agent (CPA) containing both L-glutamine and monothioglycerol (LM-CPA).
3. The composition of any one of claims 1-2, wherein the concentration of monothioglycerol is about 100-800 µM and the concentration of L-glutamine is about 20-120 mM.
4. The composition of any one of claims 1-2, wherein the composition further comprises about 18% D+raffinose pentahydrate and about 3% dehydrated skim milk.
5. The composition of any one of claims 1-2, wherein the composition protects the spermatozoon from damage or death during thawing of the cryopreserved composition.
6. The composition of claim 2, wherein the composition exhibits enhanced in vitro fertilization (IVF) rate relative to the CPA devoid of monothioglycerol.
7. The composition of any one of claims 1 and 2, wherein the subject is a mammal.
8. The composition of claim 7, wherein the mammal is selected from the group consisting of a human and a mouse. -16- 51873477.2Attorney Docket No.205961-7100WO1(00382) 9. A method of cryopreserving spermatozoon of a subject, wherein the method comprises contacting the spermatozoon with the composition of claim 1 to form a suspension and preserving the suspension in a liquid nitrogen.
10. A method of in vitro fertilization, wherein the method comprises a. cryopreserving a spermatozoon of a subject, wherein the cryopreserving comprises contacting the spermatozoon with the composition of claim 1 to form a suspension, and cryopreserving the suspension in a liquid nitrogen; b. thawing the spermatozoon suspension at about 37°C; and c. contacting the spermatozoon with an egg from a subject to form an embryo.
11. The method of claim 10, wherein the composition protects the spermatozoon from damage or death during the thawing step.
12. The method of claim 10, wherein the method exhibits enhanced in vitro fertilization (IVF) rate relative to the method that uses a CPA devoid of monothioglycerol.
13. A kit comprising the composition of any one of claims 1-2 and an instructional material for use thereof.
14. The method of any one of claims 9 and 10, wherein the subject is a mammal.
15. The method of claim 14, wherein the mammal is selected from the group consisting of a human and a mouse. -17- 51873477.2
